Gilead Sciences (NASDAQ:GILD) was upgraded by equities researchers at Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Friday.
GILD has been the topic of a number of other reports. Mizuho set a $81.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, October 15th. Credit Suisse Group cut shares of Gilead Sciences from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $67.00 to $63.00 in a report on Friday, December 13th. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Cowen reaffirmed a “buy” rating and issued a $85.00 target price on shares of Gilead Sciences in a report on Thursday. Finally, Morgan Stanley set a $75.00 price target on shares of Gilead Sciences and gave the company a “hold” rating in a report on Friday, October 25th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $79.17.
Shares of GILD stock traded up $0.05 on Friday, reaching $65.28. The stock had a trading volume of 149,314 shares, compared to its average volume of 6,647,792. The company has a quick ratio of 2.87, a current ratio of 2.96 and a debt-to-equity ratio of 1.11. The firm’s 50-day moving average is $66.10 and its two-hundred day moving average is $65.45. The firm has a market capitalization of $82.27 billion, a price-to-earnings ratio of 10.60, a P/E/G ratio of 3.95 and a beta of 1.12. Gilead Sciences has a 12 month low of $60.89 and a 12 month high of $70.50.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.74 by $0.01. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.61 billion. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. Gilead Sciences’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.84 EPS. On average, sell-side analysts forecast that Gilead Sciences will post 6.63 earnings per share for the current fiscal year.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 2,095 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $66.06, for a total transaction of $138,395.70. Following the transaction, the executive vice president now owns 17,826 shares in the company, valued at approximately $1,177,585.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 5,677 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $63.31, for a total transaction of $359,410.87. Following the transaction, the executive vice president now owns 21,521 shares in the company, valued at approximately $1,362,494.51. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,672 shares of company stock worth $2,795,780. Company insiders own 0.20% of the company’s stock.
Large investors have recently made changes to their positions in the business. First Financial Corp IN boosted its position in shares of Gilead Sciences by 286.4% during the 3rd quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 401 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $40,000. Front Row Advisors LLC boosted its position in shares of Gilead Sciences by 286.0% during the 2nd quarter. Front Row Advisors LLC now owns 691 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 512 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of Gilead Sciences by 30.7% during the 3rd quarter. Larson Financial Group LLC now owns 826 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 194 shares in the last quarter. Finally, Reilly Financial Advisors LLC boosted its position in shares of Gilead Sciences by 43.5% during the 3rd quarter. Reilly Financial Advisors LLC now owns 890 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 270 shares in the last quarter. Hedge funds and other institutional investors own 79.28% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
